• Nanoparticle-Mediated PTEN mRNA Delivery Reverses Trastuzuma

  2026-06-22

  This study demonstrates that tumor microenvironment-responsive nanoparticles can systemically deliver PTEN mRNA to overcome trastuzumab resistance in HER2-positive breast cancer. By restoring PTEN and inhibiting PI3K/Akt signaling, the approach offers a promising precision strategy for resistant cancer phenotypes.

• Ribonuclease R (20 U/μL): Streamlining Circular RNA Enrichme

  2026-06-22

  Ribonuclease R (RNase R) (20 U/μL) from APExBIO transforms circular RNA research by delivering highly selective linear RNA digestion, critical for advanced RNA structure-function and inflammation studies. Explore optimized workflows, troubleshooting strategies, and the translational impact of RNase R in dissecting complex RNA-mediated pathways.

• Synthetic Modified mRNA Enables Rapid hiPSC-to-Oligodendrocy

  2026-06-21

  The referenced study demonstrates a non-viral, synthetic modified mRNA (smRNA) approach for efficiently differentiating human-induced pluripotent stem cells (hiPSCs) into functional oligodendrocytes. By using OLIG2 S147A smRNA, the protocol achieves high-purity oligodendrocyte progenitor cells in six days, offering a safer and faster alternative to traditional methods for cell therapy and disease modeling.

• DFCP1 Modulates Starvation-Driven Lipid Droplet Lipolysis vi

  2026-06-20

  The reference study identifies DFCP1 as a nutrient-sensitive regulator of lipid droplet metabolism, acting through direct modulation of ATGL-mediated lipolysis during starvation. These insights clarify key molecular mechanisms in lipid mobilization and have implications for metabolic disease research and advanced protein stability workflows.

• Sodium Ascorbate: From Molecular Mechanism to Oncology Model

  2026-06-19

  Explore the advanced mechanistic role of sodium ascorbate, a mineral salt of ascorbic acid, in precise oncology research. This in-depth analysis reveals how nuanced ROS modulation and necrotic tumor cell death inform the next generation of glioblastoma and immunotherapy modeling.

• SIRT1-Regulated Ran Lactylation Drives Astrocyte Polarizatio

  2026-06-19

  This study uncovers a novel mechanism in which lactate-induced lactylation of the small GTPase Ran at lysine 123, regulated by SIRT1, enables astrocyte polarization following oxygen-glucose deprivation/reoxygenation (OGD/R). These findings highlight the importance of non-histone protein lactylation in central nervous system injury repair, offering new molecular targets for therapeutic intervention.

• Kanamycin Sulfate: Water-Soluble Antibiotic for Applied Rese

  2026-06-18

  Kanamycin Sulfate empowers researchers with a reliable, water-soluble antibiotic for precision selection and mechanistic studies in antibiotic resistance and RNA therapeutics. This guide details optimized workflows, protocol parameters, and troubleshooting strategies that elevate experimental success across microbiology and molecular biology domains.

• Mechanistic Precision in Protein Extraction for Translationa

  2026-06-18

  A deep dive into the mechanistic underpinnings of the MAPK10/KRT16 axis in NSCLC metastasis and the strategic value of advanced plant cell lysis workflows for translational researchers. This article bridges high-fidelity protein sample preparation with the frontiers of molecular oncology, offering protocol insights and competitive guidance for maximizing downstream assay reliability—anchored in the unique capabilities of APExBIO’s Plant Cell Lysis Buffer for WB and IP.

• EZ Cap EGFP mRNA 5-moUTP: Optimizing mRNA Delivery & Imaging

  2026-06-17

  EZ Cap™ EGFP mRNA (5-moUTP) empowers researchers to achieve robust, immune-silent fluorescence expression for gene regulation, cell viability, and in vivo imaging studies. This guide translates recent machine learning-driven delivery insights and real-world workflow strategies into actionable protocols and troubleshooting tips.

• Metabolic Intervention Enhances Ferroptosis and Cuproptosis

  2026-06-17

  This study introduces a nanosystem that synchronously sensitizes tumor cells to both ferroptosis and cuproptosis by targeting glycolysis and NAD+ metabolism. The dual activation not only promotes regulated cell death but also remodels the tumor immune microenvironment, pointing to new strategies for advanced cancer therapies.

• Practical Use of HyperPFU™ High-Fidelity DNA Polymerase in P

  2026-06-16

  HyperPFU™ high-fidelity DNA polymerase addresses the challenges of amplifying long, GC-rich, or otherwise difficult DNA templates by delivering high fidelity and robust performance. It is best suited for workflows requiring blunt-ended PCR products for cloning or sequencing, but should not be used when 3'-A overhangs or sticky ends are required.

• Paclitaxel (Taxol): Strategic Leverage in Translational Onco

  2026-06-16

  This thought-leadership article explores Paclitaxel (Taxol) as a mechanistic anchor and strategic catalyst for translational cancer research. Blending biological rationale, evidence-driven protocol guidance, and competitive insight, it frames Paclitaxel’s role beyond legacy applications, emphasizing innovative assay design and actionable translational strategies. By integrating recent findings on in vitro methodologies and cross-linking to advanced workflow content, the piece delivers practical vision for researchers seeking to elevate both preclinical rigor and clinical relevance.

• SR 11302: Shaping AP-1 Inhibition for Transformative Oncolog

  2026-06-15

  This thought-leadership article examines the transformative potential of SR 11302—a selective AP-1 transcription factor inhibitor—for translational cancer research. Bridging mechanistic insights and practical guidance, it synthesizes recent immunomodulatory findings, strategic AP-1 targeting, and protocol best practices. The article distinguishes itself by contextualizing SR 11302's role in modern oncology, highlighting competitive advantages, and offering a future-focused outlook for researchers.

• Redefining Inflammasome Research: NBC19 and Translational St

  2026-06-15

  Explore the mechanistic and translational advances enabled by NBC19, a potent NLRP3 inflammasome inhibitor, in dissecting the interplay between metabolism-driven inflammation and cytokine release. This article synthesizes emerging evidence, competitive context, and protocol recommendations to empower next-generation inflammation research.

• RG108: DNA Methyltransferase Inhibitor for Epigenetic Modula

  2026-06-14

  RG108 is a small-molecule DNA methyltransferase inhibitor uniquely enabling targeted DNA demethylation and reactivation of silenced tumor suppressor genes, while minimizing cytotoxicity and off-target effects. This guide details advanced protocols, troubleshooting strategies, and novel in vivo applications that set RG108 apart in both cancer research and cellular reprogramming workflows.

11452 records 1/764 page Next 12345 下5页 Last page